EUCTR2019-002383-27-NL进行中（未招募）1 期
An exploratory, single-center, double-blinded, healthy volunteer controlled study to characterize psoriasis patients and explore novel biomarkers for the treatment response of psoriasis with a multi-modal patient profiling approach
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Healthy volunteers
- •Eligible healthy volunteers must meet all of the following inclusion criteria at screening:
- •1.Male or non-pregnant female subjects, 18 to 75 years of age (inclusive); during COVID-19 pandemic this is set to 18 to 69 year of age (inclusive)
- •2.Healthy as defined by the absence of any uncontrolled active or uncontrolled chronic disease following a medical and surgical history, documentation of general symptoms, and a symptom-directed physical examination including vital signs;
- •3.Willing to give written informed consent and willing and able to comply with the study protocol;
- •Psoriasis patients
- •Eligible psoriasis patients must meet all of the following inclusion criteria at screening:
- •1.Male or non-pregnant female subjects, 18 to 75 years of age (inclusive); during COVID-19 pandemic this is set to 18 to 69 year of age (inclusive)
- •2.Diagnosed with plaque psoriasis at least 6 months prior to study participation
- •3.Willing to discontinue any psoriasis therapy other than emollients.
- •4.Having mild ((BSA PASI =1 and = 5) (BSA =1% andPASI = 5%) or moderate-to-severe (PASI = 10) plaque psoriasis
- •5.Currently not using psoriasis medication and = 2 plaques suitable for repeated biopsies and target lesion assessments. At least one of these lesions must be located on the extremities, preferably on the elbow or knee, with a minimal target lesion score between 6 and 9. Or, when currently using psoriasis medication and insufficient lesional skin is present, willing to discontinue treatment awaiting rescreening (see also exclusion criteria 3 for psoriatic patients);
- •6.Willing to give written informed consent and willing and able to comply with the study protocol;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Healthy volunteers
- •Eligible healthy volunteers must meet none of the following exclusion criteria at screening:
- •1.History or symptoms of any uncontrolled, significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives, in the opinion of the Investigator;
- •2.History of immunological abnormality (e.g., immune suppression, severe allergy or anaphylaxis) that may interfere with study objectives, in the opinion of the Investigator;
- •3.Known infection requiring antibiotic therapy within the last three months prior to the study;
- •4.Immunosuppressive or immunomodulatory treatment within 30 days prior to the study;
- •5.Body mass index (BMI) = 18.0 or = 40.0 kg/m2; during COVID-19 pandemic only = 18.0 or > 33.0 kg/m2
- •6.Participation in an investigational drug study within 3 months prior to screening or more than 4 times a year;
- •7.Previous participation in an investigational drug study involving the dosing of an investigational compound targeting an immune pathway within one year prior to screening;
- •8.Loss or donation of blood over 500 mL within three months prior to screening;
- •9.The use of any medication or vitamin/mineral/herbal/dietary supplement within less than 5 half-lives prior to study participation, if the Investigator judges that it may interfere with the study objectives. The use of paracetamol (up to 4 g/day) and ibuprofen (up to 1 g/day) is allowed;
- •10.History of alcohol consumption exceeding 5 standard drinks per day on average within 3 months of screening. Alcohol consumption will be prohibited from at least 12 hours preceding each study visit;
- •11.Any other condition that could interfere with the conduct of the study or the study objectives, in the opinion of the Investigator.
- •12.During COVID-19 pandemic: presence of high risk comorbidities: such as cardiovascular, respiratory or immune system disorders
- •Psoriasis patients
- •Eligible psoriasis patients must meet none of the following exclusion criteria at screening:
- •1.Having primarily erythrodermic, pustular or guttate psoriasis;
- •2.Having medication-induced psoriasis;
- •3.Having previously failed on anti-IL23 therapy;
- •4.Having received treatments for psoriasis within the following intervals prior to the start of the study:
- •a.< 2 weeks for topical treatment, e.g. retinoids, corticosteroids, vitamin D analogs
- •b.< 4 weeks for phototherapy, e.g. PUVA, PDT
- •c.< 4 weeks for non-biologic systemic treatment, e.g. retinoids, methotrexate, cyclosporine, fumaric acid esters
- •d.< 4 weeks for etanercept
- •e.< 8 weeks for adalimumab
- •f.< 3 months for anti-IL17, anti-IL12(/23) and anti-IL23 treatments
- •5.History or symptoms of any significant uncontrolled disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives, in the opinion of the Investigator, excluding psoriasis and conditions that are related to psoriasis;
- •6.History of immunological abnormality (e.g., immune suppression, severe allergy or anaphylaxis) that may interfere with study objectives, in the opinion of the Investigator;
- •7.Known infection requiring antibiotic therapy within the last 3 months prior to the study, including latent tuberculosis;
- •8.Systemic immunosuppressive or immunomodulatory treatment within 30 days prior to the study;
研究者
相似试验
已完成
4 期
An exploratory, single-center, double-blinded, healthy volunteer controlled study to characterize psoriasis patients and explore novel biomarkers for the treatment response of psoriasis with a multi-modal patient profiling approachNL-OMON52891Centre for Human Drug Research50
进行中（未招募）
不适用
An exploratory, randomised, double-blind, single-dummy, placebo controlled, parallel group study to demonstrate the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) in addition to pregabalin compared to pregabalin alone in opioid-naïve subjects treated with pregabalin suffering from severe pain due to diabetic polyneuropathyEUCTR2008-005815-17-DEMundipharma Research GmbH & Co. KG80
进行中（未招募）
1 期
An exploratory, randomised, double-blind, single-dummy, placebo controlled, parallel group study to demonstrate the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) in addition to pregabalin compared to pregabalin alone in opioid-naïve subjects treated with pregabalin suffering from moderate to severe pain due to diabetic polyneuropathyModerate to severe pain due to diabetic polyneuropathyMedDRA version: 9.1Level: LLTClassification code 10012685Term: Diabetic polyneuropathyEUCTR2008-005815-17-HUMundipharma Research GmbH & Co. KG80
进行中（未招募）
不适用
An exploratory, randomised, double-blind, single-dummy, placebo controlled, parallel group study to demonstrate the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) in addition to pregabalin compared to pregabalin alone in opioid-naïve subjects treated with pregabalin suffering from severe pain due to diabetic polyneuropathySevere pain due to diabetic polyneuropathyMedDRA version: 9.1Level: LLTClassification code 10012685Term: Diabetic polyneuropathyEUCTR2008-005815-17-CZMundipharma Research GmbH & Co. KG80
进行中（未招募）
1 期
idocaine/diclofenac epolamine patch (GRT7019) Phase II proof-of-concept trial in patients with chronic pain due to knee osteoarthritis.MedDRA version: 20.0Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859osteoarthritisEUCTR2016-002611-18-ESGrünenthal GmbH300